Carbapenem-Resistant Enterobacteriaceae Detection Practices in California: What Are We Missing? | Zendy

Romney M. Humphries | Zendy; Janet A. Hindler | Zendy; Erin Epson | Zendy; Sam Horwich-Scholefield | Zendy; Loren G. Miller | Zendy; Job Mendez | Zendy; Jeremias Martinez | Zendy; Jacob Sinkowitz | Zendy; Darren Sinkowtiz | Zendy; Christina Hershey | Zendy; Patricia Márquez | Zendy; Sandeep Bhaurla | Zendy; Marcelo Moran | Zendy; Lindsey Pandes | Zendy; Dawn Terashita | Zendy; James A. McKinnell | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Carbapenem-Resistant Enterobacteriaceae Detection Practices in California: What Are We Missing?

Author(s) -

Romney M. Humphries,

Janet A. Hindler,

Erin Epson,

Sam Horwich-Scholefield,

Loren G. Miller,

Job Mendez,

Jeremias Martinez,

Jacob Sinkowitz,

Darren Sinkowtiz,

Christina Hershey,

Patricia Márquez,

Sandeep Bhaurla,

Marcelo Moran,

Lindsey Pandes,

Dawn Terashita,

James A. McKinnell

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix942

Subject(s) - ertapenem , meropenem , imipenem , carbapenem , carbapenem resistant enterobacteriaceae , medicine , enterobacteriaceae , microbiology and biotechnology , antibiotics , biology , antibiotic resistance , gene , genetics , escherichia coli

The Clinical and Laboratory Standards Institute (CLSI) revised the carbapenem breakpoints for Enterobacteriaceae in 2010. The number of hospitals that adopted revised breakpoints and the clinical impact of delayed adoption has not been explored.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research